AVITA Medical (RCEL) Liabilities and Shareholders Equity (2020 - 2025)

AVITA Medical's Liabilities and Shareholders Equity history runs 6 years deep, the most recent figure standing at $56.4 million for Q4 2025.

• Quarterly Liabilities and Shareholders Equity fell 29.25% year-over-year to $56.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $247.8 million (down 28.37% YoY) and the FY2025 annual result came in at $56.4 million, down 29.25% from the prior year.
• Liabilities and Shareholders Equity was $56.4 million for Q4 2025 at AVITA Medical, down from $63.7 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $128.1 million in Q1 2021 and bottomed at $56.4 million in Q4 2025.
• A 5-year average of $93.2 million and a median of $95.0 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2021 — Liabilities and Shareholders Equity soared 67.4% — and 2025, when it slumped 33.81%.
• AVITA Medical's Liabilities and Shareholders Equity stood at $116.0 million in 2021, then slipped by 15.3% to $98.3 million in 2022, then advanced by 13.61% to $111.6 million in 2023, then decreased by 28.6% to $79.7 million in 2024, then decreased by 29.25% to $56.4 million in 2025.
• Business Quant data shows RCEL's Liabilities and Shareholders Equity at $56.4 million in Q4 2025, $63.7 million in Q3 2025, and $58.1 million in Q2 2025.